CD40 expression by human peripheral blood eosinophils.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Print ISSN: 0021-9738 (Print) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
    • Publication Information:
      Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
      Original Publication: New Haven [etc.] American Society for Clinical Investigation.
    • Subject Terms:
      CD40 Antigens/*blood ; Eosinophils/*immunology; Antibodies, Monoclonal/pharmacology ; Base Sequence ; CD40 Antigens/chemistry ; CD40 Antigens/genetics ; Cross-Linking Reagents ; DNA Primers/genetics ; Eosinophils/metabolism ; Gene Expression ; Granulocyte-Macrophage Colony-Stimulating Factor/antagonists & inhibitors ; Granulocyte-Macrophage Colony-Stimulating Factor/immunology ; Granulocyte-Macrophage Colony-Stimulating Factor/metabolism ; Humans ; Immunohistochemistry ; Inflammation/genetics ; Inflammation/immunology ; Molecular Sequence Data ; Nasal Polyps/genetics ; Nasal Polyps/immunology ; Polymerase Chain Reaction ; RNA, Messenger/genetics ; RNA, Messenger/metabolism
    • Abstract:
      In this study, we have investigated CD40 expression in human peripheral blood eosinophils and in human chronically inflamed nasal tissues, i.e., nasal polyps. We show by both reverse transcriptase-PCR and Northern blot analysis that eosinophils from allergic subjects express human CD40 mRNA. We also show that constitutive CD40 mRNA expression in eosinophils could be upregulated by exposure to IgA immune complexes and downregulated by IL-10 and the synthetic steroid budesonide. In addition, we demonstrate that eosinophils express CD40 protein by flow cytometry. Such expression is biologically functional as cross-linking CD40 with CD40 mAbs enhances eosinophil survival in a dose-dependent fashion; in addition, CD40 ligation stimulates eosinophils to release GM-CSF. CD40-mediated eosinophil survival was largely inhibited by an anti-GM-CSF neutralizing antibody suggesting GM-CSF involvement in the survival enhancing mechanism. CD40 mRNA was also detected in total RNA extracted from nasal polyp tissues but not in RNA isolated from normal nasal mucosa (inferior turbinate); by immunohistochemistry, we were able to detect immunoreactive CD40 protein in a variety of cell types in the polyp stroma, but primarily in eosinophils. These observations suggest previously unforeseen interactions between eosinophils and cells expressing the CD40 ligand and, thus, novel pathways by which eosinophils may contribute to the regulation of airway inflammation.
    • References:
      Cancer Immunol Immunother. 1985;20(1):23-8. (PMID: 2998589)
      Clin Immunol Immunopathol. 1995 Oct;77(1):42-51. (PMID: 7554483)
      J Exp Med. 1987 Jul 1;166(1):129-41. (PMID: 3110347)
      Anal Biochem. 1987 Apr;162(1):156-9. (PMID: 2440339)
      J Immunol. 1989 Apr 1;142(7):2393-400. (PMID: 2926137)
      EMBO J. 1989 May;8(5):1403-10. (PMID: 2475341)
      Nature. 1989 Dec 21-28;342(6252):929-31. (PMID: 2594086)
      Cell. 1990 Apr 20;61(2):361-70. (PMID: 2158863)
      Int Arch Allergy Appl Immunol. 1990;91(2):198-203. (PMID: 1971264)
      Science. 1990 May 25;248(4958):1019-23. (PMID: 2160731)
      Tissue Antigens. 1990 Jul;36(1):33-6. (PMID: 1701063)
      Am J Respir Cell Mol Biol. 1991 Jun;4(6):525-31. (PMID: 2054193)
      J Allergy Clin Immunol. 1991 Sep;88(3 Pt 1):365-75. (PMID: 1890265)
      J Immunol. 1992 Aug 1;149(3):775-82. (PMID: 1378865)
      EMBO J. 1992 Dec;11(12):4313-21. (PMID: 1385114)
      Eur J Immunol. 1992 Dec;22(12):3191-4. (PMID: 1280226)
      J Exp Med. 1992 Dec 1;176(6):1543-50. (PMID: 1281209)
      J Exp Med. 1993 Aug 1;178(2):669-74. (PMID: 7688031)
      Science. 1993 Sep 3;261(5126):1328-30. (PMID: 7689748)
      Eur J Immunol. 1993 Sep;23(9):2368-71. (PMID: 8103750)
      Nature. 1993 Sep 23;365(6444):340-3. (PMID: 7690905)
      J Exp Med. 1994 Feb 1;179(2):703-8. (PMID: 8294877)
      J Clin Invest. 1994 Sep;94(3):1333-8. (PMID: 7521888)
      J Exp Med. 1994 Oct 1;180(4):1263-72. (PMID: 7523569)
      J Immunol. 1995 Feb 1;154(3):1470-80. (PMID: 7529804)
      Eur J Immunol. 1995 Mar;25(3):863-5. (PMID: 7705419)
      J Immunol. 1995 May 15;154(10):4996-5010. (PMID: 7537298)
      J Exp Med. 1995 Jul 1;182(1):33-40. (PMID: 7540655)
      J Leukoc Biol. 1995 Aug;58(2):209-16. (PMID: 7543921)
      J Immunol. 1995 Sep 15;155(6):3234-44. (PMID: 7673736)
      J Clin Invest. 1986 Nov;78(5):1220-8. (PMID: 3021817)
    • Grant Information:
      AI20241 United States AI NIAID NIH HHS; HL46563 United States HL NHLBI NIH HHS
    • Accession Number:
      0 (Antibodies, Monoclonal)
      0 (CD40 Antigens)
      0 (Cross-Linking Reagents)
      0 (DNA Primers)
      0 (RNA, Messenger)
      83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
    • Publication Date:
      Date Created: 19960401 Date Completed: 19960507 Latest Revision: 20181113
    • Publication Date:
      20240829
    • Accession Number:
      PMC507241
    • Accession Number:
      10.1172/JCI118603
    • Accession Number:
      8601642